{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:22:37Z","timestamp":1790882557305,"version":"4.1.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Schizoaffective disorder is a severe psychiatric condition characterized by mood disturbances and psychotic symptoms. Standard treatments, primarily pharmacological, often fail to control symptoms fully and can lead to significant metabolic side effects. Emerging evidence suggests that ketogenic metabolic therapy (KMT), also known as the ketogenic diet, may offer a powerful alternative to conventional treatments for mood components and resolve psychiatric symptoms in patients with schizoaffective disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This case series investigates the effects of KMT on two individuals diagnosed with schizoaffective disorder who pursued this therapy due to the ineffectiveness of conventional treatments. Both case presentations followed a modified ketogenic diet with medical oversight. Symptom changes in mood were assessed using validated tools, including the Generalized Anxiety Disorder-7 (GAD-7), Depression Anxiety Stress Scales (DASS-42), PTSD Checklist for DSM-5 (PCL-5), and Patient Health Questionnaire-9 (PHQ-9).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both case presentations experienced the complete cessation of psychotic symptoms and improvements in mood. Case 1, a 17-year-old female, achieved full remission of severe suicidal ideation, hallucinations, and anxiety within 6\u202fweeks, with sustained improvements at a 24-week follow-up. Case 2, a 32-year-old female, achieved full remission of chronic psychotic and mood symptoms by 6\u202fmonths. Patients either achieved full psychiatric deprescription or were in the process of deprescription at time of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case series demonstrates that ketogenic metabolic therapy can resolve chronic psychotic and mood symptoms in patients with schizoaffective disorder, leading to full remission and significant functional recovery and reported improvements in quality of life that extend beyond symptom control with standard of care interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2025.1506304","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:10:42Z","timestamp":1738926642000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Ketogenic metabolic therapy for schizoaffective disorder: a retrospective case series of psychotic symptom remission and mood recovery"],"prefix":"10.3389","volume":"12","author":[{"given":"Nicole","family":"Laurent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L.","family":"Bellamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Tague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donika","family":"Hristova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ally","family":"Houston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"ref1","first-page":"47","article-title":"Schizoaffective disorder: a review","volume":"31","author":"Miller","year":"2019","journal-title":"Ann Clin Psychiatry Off J Am Acad Clin Psychiatr"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S2215-0366(15)00115-7","article-title":"Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses","volume":"2","author":"Henderson","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"ref3","first-page":"410","article-title":"Metabolic issues in psychotic disorders with the focus on first-episode patients: a review","volume":"25","author":"Britvic","year":"2013","journal-title":"Psychiatr Danub"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1343427","DOI":"10.3389\/fpsyt.2024.1343427","article-title":"Shared and unique characteristics of metabolic syndrome in psychotic disorders: a review","volume":"15","author":"Saccaro","year":"2024","journal-title":"Front Psychol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1177\/070674370605100803","article-title":"The metabolic effects of antipsychotic medications","volume":"51","author":"Newcomer","year":"2006","journal-title":"Can J Psychiatr Rev Can Psychiatr"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.24869\/psyd.2020.46","article-title":"A meta-analysis of abnormal glucose metabolism in FIRST-episode drug-naive schizophrenia","volume":"32","author":"Yang","year":"2020","journal-title":"Psychiatr Danub"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"116220","DOI":"10.1016\/j.psychres.2024.116220","article-title":"Schizophrenia, a disease of impaired dynamic metabolic flexibility: a new mechanistic framework","volume":"342","author":"Sarnyai","year":"2024","journal-title":"Psychiatry Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/jamapsychiatry.2016.3803","article-title":"Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and Meta-analysis","volume":"74","author":"Pillinger","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/s41380-018-0035-3","article-title":"Neuron-specific deficits of bioenergetic processes in the dorsolateral prefrontal cortex in schizophrenia","volume":"24","author":"Sullivan","year":"2019","journal-title":"Mol Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1038\/s41380-022-01494-x","article-title":"Schizophrenia: a disorder of broken brain bioenergetics","volume":"27","author":"Henkel","year":"2022","journal-title":"Mol Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e220009","DOI":"10.20900\/jpbs.20220009","article-title":"The role of ketogenic metabolic therapy on the brain in serious mental illness: a review","volume":"7","author":"Sethi","year":"2022","journal-title":"J Psychiatry Brain Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1444483","DOI":"10.3389\/fnut.2024.1444483","article-title":"The effects of ketogenic metabolic therapy on mental health and metabolic outcomes in schizophrenia and bipolar disorder: a randomized controlled clinical trial protocol","volume":"11","author":"Longhitano","year":"2024","journal-title":"Front Nutr"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1017\/S003329172200174X","article-title":"Brain glucose metabolism in schizophrenia: a systematic review and meta-analysis of 18FDG-PET studies in schizophrenia","volume":"53","author":"Townsend","year":"2023","journal-title":"Psychol Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40501-024-00339-4","article-title":"The ketogenic diet as a Transdiagnostic treatment for neuropsychiatric disorders: mechanisms and clinical outcomes","volume":"12","author":"Anderson","year":"2024","journal-title":"Curr Treat Options Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/MED.0000000000000564","article-title":"Ketogenic diet as a metabolic treatment for mental illness","volume":"27","author":"Norwitz","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.schres.2019.03.019","article-title":"The ketogenic diet and remission of psychotic symptoms in schizophrenia: two case studies","volume":"208","author":"Palmer","year":"2019","journal-title":"Schizophr Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"115866","DOI":"10.1016\/j.psychres.2024.115866","article-title":"Ketogenic diet intervention on metabolic and psychiatric health in bipolar and schizophrenia: a pilot trial","volume":"335","author":"Sethi","year":"2024","journal-title":"Psychiatry Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"951376","DOI":"10.3389\/fpsyt.2022.951376","article-title":"The ketogenic diet for refractory mental illness: a retrospective analysis of 31 inpatients","volume":"13","author":"Danan","year":"2022","journal-title":"Front Psychol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1394679","DOI":"10.3389\/fnut.2024.1394679","article-title":"Retrospective case study: ketogenic metabolic therapy in the effective management of treatment-resistant depressive symptoms in bipolar disorder","volume":"11","author":"Laurent","year":"2024","journal-title":"Front Nutr"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1192\/bjo.2023.568","article-title":"Pilot study of a ketogenic diet in bipolar disorder","volume":"9","author":"Needham","year":"2023","journal-title":"BJPsych Open"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0005-7967(94)00075-U","article-title":"The structure of negative emotional states: comparison of the depression anxiety stress scales (DASS) with the Beck depression and anxiety inventories","volume":"33","author":"Lovibond","year":"1995","journal-title":"Behav Res Ther"},{"key":"ref23","first-page":"42","volume-title":"Manual for the depression anxiety stress scales","author":"Lovibond","year":"1996"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e0161645","DOI":"10.1371\/journal.pone.0161645","article-title":"Psychometric validation of the English and French versions of the posttraumatic stress disorder checklist for DSM-5 (PCL-5)","volume":"11","author":"Ashbaugh","year":"2016","journal-title":"PLoS One"},{"key":"ref25","unstructured":"Weathers\n              F. W.\n            \n            \n              Litz\n              B. T.\n            \n            \n              Keane\n              T. M.\n            \n            \n              Palmieri\n              P. A.\n            \n            \n              Marx\n              B. P.\n            \n            \n              Schnurr\n              P. P.\n            \n          \n          \n          2013"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3928\/0048-5713-20020901-06","article-title":"The PHQ-9: a new depression diagnostic and severity measure","volume":"32","author":"Kroenke","year":"2002","journal-title":"Psychiatr Ann"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12888-021-03661-w","article-title":"The validity and reliability of the PHQ-9 on screening of depression in neurology: a cross sectional study","volume":"22","author":"Sun","year":"2022","journal-title":"BMC Psychiatry"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2025.1506304\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:10:48Z","timestamp":1738926648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2025.1506304\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":28,"alternative-id":["10.3389\/fnut.2025.1506304"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2025.1506304","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"article-number":"1506304"}}